,2,3 Recent studies have shown that glucagon-like peptide-1 receptor agonists (GLP-1RA), an anti-diabetes and anti-obesity drug class, have a beneficial impact on cardiovascular outcomes in patients with metabolic disorders such as obesity and type II diabetes mellitus.4 Here, GLP1R is linked to Obesity.